EU Commission President Ursula von der Leyen is convinced she will achieve a “noticeable improvement” in vaccination backlogs in Europe by summer. Biontech could supply more doses than initially thought, she said, adding Johnson & Johnson’s vaccine.
“We were looking at six manufacturers, three of which have now been approved and are in demand worldwide, and two are close to approval,” she said. As a result, she said, the EU has backed the “right horses.” The broad range of vaccines can also be used against the mutations, she said. Preparations are already underway with the pharmaceutical companies to be able to adapt the vaccines if further dangerous variants appear. The EU is therefore investing in research and a faster flow of data. All EU member states are called upon to conduct gene analyses in order to quickly detect and trace new mutations. Finally, a network of production sites will be created to rapidly produce the improved vaccine.
- source: derstandard.at/picture:pixabay.com
This post has already been read 137 times!